| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
BASEL, Switzerland and LONDON and NEW YORK, November 9, 2026 – Roivant (Nasdaq: ROIV) today reported its financial results for the second quarter ended September 30, 2026, and provided a business update. |
| 21 Oct 2026 |
8-K: Regulation FD Disclosure
Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU) |
| 18 Sep 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On September 16, 2026, Roivant Sciences Ltd. (the “Company”) held its 2026 Annual General Meeting of Shareholders. At that meeting, the shareholders considered and acted upon three proposals as described in more detail in the Company’s p... |
| 08 Sep 2026 |
8-K: Regulation FD Disclosure
Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study |
| 28 Aug 2026 |
8-K: Other Events
LISRAYA (brepocitinib) Approved for Treatment of Patients with Dermatomyositis August 28, 2026 For investor audiences only |
| 27 Aug 2026 |
8-K: Regulation FD Disclosure
Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S. |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
BASEL, Switzerland and LONDON and NEW YORK, August 6, 2026 – Roivant (Nasdaq: ROIV) today reported its financial results for the first quarter ended June 30, 2026, and provided a business update. |
| 20 May 2026 |
8-K: Results of Operations and Financial Condition
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update |
| 02 Apr 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) |
| 03 Mar 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure +1 more
Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna |
| 03 Mar 2026 |
8-K: Regulation FD Disclosure
FDA assigns PDUFA target action date in the third quarter of calendar year 2026 with launch expected at the end of September 2026 |
| 06 Feb 2026 |
8-K: Results of Operations and Financial Condition
Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025 |
| 11 Dec 2025 |
8-K: Regulation FD Disclosure
Forward-Looking Statements This presentation includes forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such stateme... |
| 10 Nov 2025 |
8-K: Results of Operations and Financial Condition
BASEL, Switzerland and LONDON and NEW YORK, November 10, 2025 – Roivant (Nasdaq: ROIV) today reported its financial results for the second quarter ended September 30, 2025, and provided a business update. |
| 17 Sep 2025 |
8-K: Regulation FD Disclosure; Other Events
Brepocitinib in DM: VALOR Topline Results September 17, 2025 |
| 11 Sep 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On September 10, 2025, Roivant Sciences Ltd. (the “Company”) held its 2025 Annual General Meeting of Shareholders. At that meeting, the shareholders considered and acted upon three proposals as described in more detail in the Company’s P... |
| 03 Sep 2025 |
8-K: Regulation FD Disclosure; Other Events
Targeted science, Tailored solutions for people with autoimmune disease Batoclimab Graves’ Disease Proof-of-Concept Study Remission Data September 2025 |
| 11 Aug 2025 |
8-K: Results of Operations and Financial Condition
BASEL, Switzerland and LONDON and NEW YORK, August 11, 2025 – Roivant (Nasdaq: ROIV) today reported its financial results for the first quarter ended June 30, 2025, and provided a business update. |
| 25 Jun 2025 |
8-K: Other Events
On June 24, 2025, the board of directors of Roivant Sciences Ltd. (the “Company”) authorized a common share repurchase program allowing for repurchases of the Company’s common shares in an aggregate amount of up to $500 million (excludin... |
| 29 May 2025 |
8-K: Results of Operations and Financial Condition
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update |
Loading...